A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
To investigate esophageal reflux condition in patients with non-erosive gastroesophageal
reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week
treatment with 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)).